Edoxaban Fails to Lower Stroke Risk in ENRICH-AF Trial
The study finds the drug does not reduce stroke risk but increases major bleeding in patients with prior hemorrhage.
Updated on Oct. 23, 2026 in Stroke
Live Poll
Do you trust clinical trial findings to guide your personal decisions about long-term medication use?
The ENRICH-AF clinical trial shows that edoxaban failed to significantly reduce the risk of stroke or systemic embolism in patients with atrial fibrillation and a history of intracranial hemorrhage. Instead, the drug was associated with a higher incidence of major bleeding compared to non-anticoagulant medical therapy.
Why it matters
The findings are critical for physicians managing stroke prevention in high-risk patients who have previously suffered an intracranial bleed. These results highlight the need for careful balancing between preventing future strokes and avoiding dangerous hemorrhage events.
The study followed 948 patients with a mean age of 77 years for an average of 3 years. Patients receiving edoxaban faced an 11.6% rate of major bleeding compared to 5.2% for the control group, yielding a hazard ratio of 2.23.
The players
World Stroke Congress
This is a premier international event where global researchers gather to share the latest developments in stroke care and prevention.
The details
The prospective, randomized open-label trial compared edoxaban doses of 30 or 60 mg against non-anticoagulant therapy. Researchers observed that the primary composite endpoint occurred in 11.8% of the edoxaban group versus 12.8% in the control group, showing no significant efficacy benefit.
Timeline
October 21-23, 2026: Trial results were presented at the World Stroke Congress in Seoul.
Health Landscape
These findings contribute to a growing body of research, including the ASPIRE trial, focused on optimizing secondary stroke prevention strategies. This data marks an important step in defining clinical guidelines for patients with complex histories of atrial fibrillation and hemorrhage.
Patients with a history of intracranial hemorrhage should consult with their neurologists regarding these findings to evaluate their current anticoagulant treatment plans. These results emphasize that blood-thinning therapies must be personalized to avoid significant bleeding risks.
The takeaway
Clinicians and patients should remain cautious when using anticoagulants after a brain bleed due to the elevated risk of major bleeding shown in recent trials. Further studies like the upcoming COCROACH meta-analysis are needed to provide clearer guidance for this vulnerable patient group.
Further reading
For more information on current treatment standards and ongoing research, visit the Stroke section.
More information
View the ENRICH-AF clinical trial details to learn more about the study design.
Live Poll
Do you trust clinical trial findings to guide your personal decisions about long-term medication use?
